Literature DB >> 24900531

Four lessons from global health drug discovery: medicine for an ailing industry?

Richard L Elliott1.   

Abstract

In recent years, the pharmaceutical industry has faced many challenges to its business model, undergoing tremendous change and turmoil to survive. Are there any lessons to be drawn from drug discovery focused on Global Health, where there is little market incentive?

Year:  2012        PMID： 24900531      PMCID： PMC4025862          DOI： 10.1021/ml3002105

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  2 in total

Review 1.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694
  2 in total
  3 in total

1.  Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.

Authors:  Dan Yan; Stefanie A Krumm; Aiming Sun; David A Steinhauer; Ming Luo; Martin L Moore; Richard K Plemper
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

Review 2.  Back to the future with phenotypic screening.

Authors:  Marguerite Prior; Chandramouli Chiruta; Antonio Currais; Josh Goldberg; Justin Ramsey; Richard Dargusch; Pamela A Maher; David Schubert
Journal:  ACS Chem Neurosci       Date:  2014-06-05       Impact factor: 4.418

3.  Novel Suppressive Effects of Ketotifen on Migration and Invasion of MDA-MB-231 and HT-1080 Cancer Cells.

Authors:  Hyun Ji Kim; Mi Kyung Park; Soo Youl Kim; Chang Hoon Lee
Journal:  Biomol Ther (Seoul)       Date:  2014-11-30       Impact factor: 4.634
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.